T45 Labs
Building and funding minimally invasive cardiovascular medical technology companies.
Company facts
- Founded
- 2020
- Employees
- 20
- Headquarters
- United States
- CEO
- Marwan Berrada-Sounni
- Type
- Private
- Funding
- Funding Round · $25M · 2025
- Subsidiaries
- VahatiCor, Advanced NanoTherapies, NuevoSono, ReCava
About
T45 Labs is a Silicon Valley-based medtech incubator and investment platform that builds and funds acquisition-ready cardiovascular companies. We reduce development risk by advancing differentiated technologies through critical clinical and regulatory milestones, partnering with physicians and entrepreneurs to bring breakthrough cardiovascular solutions to market. Our approach follows a best-follower strategy: entering validated markets, refining early concepts, and focusing on outcomes, ease of use, and cost efficiency. Through T45 Fund-I and T45 Fund-II, we build differentiated cardiovascular companies with clear paths to strategic acquisition and attractive investor returns. Our portfolio companies include VahatiCor, which is developing solutions for coronary microvascular dysfunction, and NuevoSono, which is working on next-generation intravascular ultrasound technology. We are headquartered in Santa Clara, California, and are committed to advancing breakthrough cardiovascular technologies from early development into the clinic for the physicians and patients who need them most.